Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: Effects of fluoxetine and MK-801

被引:36
作者
Farley, Severine [2 ,3 ,4 ]
Dumas, Sylvie [2 ,3 ,4 ]
El Mestikawy, Salah [1 ,2 ,3 ,4 ]
Giros, Bruno [1 ,2 ,3 ,4 ]
机构
[1] McGill Univ, Dept Psychiat, Douglas Hosp, Res Ctr, Verdun, PQ H4H 1R3, Canada
[2] INSERM, Physiopathol Malad Syst Nerveux Cent U952, F-75005 Paris, France
[3] CNRS, UMR 7224, F-75005 Paris, France
[4] Univ Paris 06, UPMC, F-75005 Paris, France
关键词
Depression; Antidepressants; MK-801; BDNF; VGLUT1; BALB/c; CHRONIC MILD STRESS; METHYL-D-ASPARTATE; NEUROTROPHIC FACTOR EXPRESSION; MAJOR DEPRESSIVE DISORDER; ELEMENT-BINDING PROTEIN; TAIL-SUSPENSION TEST; TRKB MESSENGER-RNA; NMDA RECEPTOR; EVOKED GLUTAMATE; EXTRACELLULAR GLUTAMATE;
D O I
10.1016/j.neuropharm.2011.09.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Major depression is a chronic psychiatric illness that is highly prevalent and disabling. The available medications are ineffective for many patients suggesting that differents molecular pathways could be specifically altered in the unresponsive patients. Recently, the glutamatergic system has emerged as a target in the research on depression and acute NMDA receptor blockade has been shown to produce strong antidepressant effects. We have studied the adaptations of four mice strains (C57BL/6, DBA/2, OH and BALB/c) to a chronic unpredictable stress protocol, a widely used model of depression in rodents. BALB/c mice displayed strikingly different behavioral and neurochemical adaptations compared to the other strains tested, suggesting that different molecular pathways are involved in their specific vulnerability. They became hyperactive during the dark period, anhedonic-like and displayed no alterations in the tail suspension test (TST). After chronic stress, only the BALB/c displayed an increased frontocortical VGLUT1 expression which is suggestive of a dysregulation of their prefrontal glutamatergic system, and no BDNF mRNA alteration, although the acute stress modulation of this mRNA is similar to the other strains. Chronic administration of an antagonist of NMDA receptors, MK-801, induced antidepressant-like effects in the TST for stressed BALB/c, but was ineffective for the hyperactivity and anhedonia-like behavior, in contrast to fluoxetine. Chronic MK801 was totally inactive on the behavior of stressed C57BL/6 mice. MK-801, but not fluoxetine, inhibited the VGLUT1 prefrontal increase in BALB/c. Fluoxetine increased VGLUT1 and BDNF mRNA expression in the hippocampus of the C57BL/6 but not in the BALB/c strain, suggesting a different reactivity in-between strain to both stress and antidepressant. Interestingly enough, the BDNF or VGLUT1 increase is not necessary to reverse the stress induced behavioral alterations in our experimental settings. This observation supports the conclusion that BDNF and VGLUT1 are depressive state markers, but not involved in its etiology. Finally, there is a substantial similarity between the phenotypes that are observed in the BALB/c mice and endogenous depression in humans, as well as between C57BL/6 mice and atypical depression. To have a better understanding of the variability of depression etiologies in human, and the implication of the glutamatergic system, it may be suggested that future animal studies in the mouse would systematically compare the two strains BALB/c and C57BL/6 for the identification of relevant biological mechanisms. This article is part of a special Issue entitled 'Anxiety and Depression'. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:503 / 517
页数:15
相关论文
共 106 条
[11]   Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice [J].
Boyce-Rustay, Janel M. ;
Holmes, Andrew .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (11) :2405-2414
[12]   Differential stress-induced alterations in tryptophan hydroxylase activity and serotonin turnover in two inbred mouse strains [J].
Browne, Caroline A. ;
Clarke, Gerard ;
Dinan, Timothy G. ;
Cryan, John F. .
NEUROPHARMACOLOGY, 2011, 60 (04) :683-691
[13]   Network stability through homeostatic scaling of excitatory and inhibitory synapses following inactivity in CA3 of rat organotypic hippocampal slice cultures [J].
Buckby, LE ;
Jensen, TP ;
Smith, PJE ;
Empson, RM .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2006, 31 (04) :805-816
[14]   Role of the brain-derived neurotrophic factor at glutamatergic synapses [J].
Carvalho, A. L. ;
Caldeira, M. V. ;
Santos, S. D. ;
Duarte, C. B. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S310-S324
[15]   Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists [J].
Chartoff, EH ;
Heusner, CL ;
Palmiter, RD .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (07) :1324-1333
[16]   Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication [J].
Chen, B ;
Dowlatshahi, D ;
MacQueen, GM ;
Wang, JF ;
Young, LT .
BIOLOGICAL PSYCHIATRY, 2001, 50 (04) :260-265
[17]   Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior [J].
Chourbaji, S ;
Hellweg, R ;
Brandis, D ;
Zörner, B ;
Zacher, C ;
Lang, UE ;
Henn, FA ;
Hörtnagl, H ;
Gass, P .
MOLECULAR BRAIN RESEARCH, 2004, 121 (1-2) :28-36
[18]   cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs [J].
Conti, AC ;
Cryan, JF ;
Dalvi, A ;
Lucki, I ;
Blendy, JA .
JOURNAL OF NEUROSCIENCE, 2002, 22 (08) :3262-3268
[19]   Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition [J].
Covington, Herbert E., III ;
Vialou, Vincent F. ;
LaPlant, Quincey ;
Ohnishi, Yoshinori N. ;
Nestler, Eric J. .
NEUROSCIENCE LETTERS, 2011, 493 (03) :122-126
[20]   Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test [J].
Crowley, JJ ;
Blendy, JA ;
Lucki, I .
PSYCHOPHARMACOLOGY, 2005, 183 (02) :257-264